Ovid Therapeutics Inc.2024财年第三财季实现净利润-14.01百万美元，同比减少24.53%

市场透视11-16

11月16日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2024财年第三财季净利润为-14.01百万美元，同比减少24.53%；其中营业收入为173000.00美元，同比增加58.76%，每股基本收益为-0.20美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债26.36百万美元，其中短期债务1.31百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483430671?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483430671","market":"us","top_or_hot":-1,"title":"Ovid Therapeutics Inc.2024财年第三财季实现净利润-14.01百万美元，同比减少24.53%","media":"市场透视","content":"<div>\n<p>11月16日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2024财年第三财季净利润为-14.01百万美元，同比减少24.53%；其中营业收入为173000.00美元，同比增加58.76%，每股基本收益为-0.20美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债26.36百万美元，其中短期债务1.31百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304a23b89a5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Inc.2024财年第三财季实现净利润-14.01百万美元，同比减少24.53%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Inc.2024财年第三财季实现净利润-14.01百万美元，同比减少24.53%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304a23b89a5&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2024财年第三财季净利润为-14.01百万美元，同比减少24.53%；其中营业收入为173000.00美元，同比增加58.76%，每股基本收益为-0.20美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债26.36百万美元，其中短期债务1.31百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304a23b89a5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OVID","symbol_name":"Ovid Therapeutics Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304a23b89a5&s=b","article_id":"2483430671","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304a23b89a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483430671","pubTimestamp":1731686434,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Ovid Therapeutics Inc.公布财报，公告显示公司2024财年第三财季净利润为-14.01百万美元，同比减少24.53%；其中营业收入为173000.00美元，同比增加58.76%，每股基本收益为-0.20美元。机构评级：截至2024年11月16日，当前有6家机构对Ovid Therapeutics Inc.目标价做出预测，其中目标均价为3.38美元，其中最低目标价为1.30美元，最高目标价为5.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"OVID":"Ovid Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"Ovid Therapeutics Inc. achieved net profit of-14.01 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 24.53%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"OVID":1},"content_text":"11月16日，Ovid Therapeutics Inc.（OVID.US）公布财报，公告显示公司2024财年第三财季净利润为-14.01百万美元，同比减少24.53%；其中营业收入为173000.00美元，同比增加58.76%，每股基本收益为-0.20美元。从资产负债表来看，Ovid Therapeutics Inc.（OVID.US）总负债26.36百万美元，其中短期债务1.31百万美元，资产负债比为0.04，流动比率为5.67。机构评级：截至2024年11月16日，当前有6家机构对Ovid Therapeutics Inc.目标价做出预测，其中目标均价为3.38美元，其中最低目标价为1.30美元，最高目标价为5.00美元。公司简介：Ovid Therapeutics Inc 是一家生物制药公司，致力于减少癫痫发作并切实改善罕见癫痫和癫痫相关神经系统疾病患者的生活。 该公司已经建立了差异化的药物管线，具有治疗癫痫发作的潜在一流药物作用机制。 该管线已经产生了两个具有潜在一流作用机制的癫痫项目，以及一个具有潜在一流作用机制的癫痫项目。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483430671"}